FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBecton, Dickinson and Company
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BDX
Becton, Dickinson and Company Stock AnalysisComprehensive stock analysis for Becton, Dickinson and Company (BDX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBDX
BDX
Becton, Dickinson and Company
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BDX
  1. Home
  2. Stocks
  3. Becton, Dickinson and Company

Becton, Dickinson and Company

🇺🇸BDX•NYSE

Becton, Dickinson and Company

🇺🇸BDX•NYSE
Market cap
$58.96B
Sentiment

Your view on BDX

Mkt Cap
$58.96B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Becton, Dickinson and Company

Industry
Medical - Instruments & Supplies
Sector
Healthcare
CEO
Thomas E. Polen Jr.
Headquarters
1 Becton Drive, Franklin Lakes, NJ, US
Industry
Medical - Instruments & Supplies
Sector
Healthcare
CEO
Thomas E. Polen Jr.
Headquarters
1 Becton Drive, Franklin Lakes, NJ, US
Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.

The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products.

The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Becton, Dickinson and Company from FRC's valuation model, read against the market price. BDX last traded at $216.47, 52.2× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Becton, Dickinson and Company. Starting points for Becton, Dickinson and Company: P/E 52.2, EPS $4.19, beta 0.28 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Becton, Dickinson and Company. Becton, Dickinson and Company paid $3.98 per share over the last year — a 1.8% yield at the current $216.47 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Becton, Dickinson and Company. Trailing twelve-month EPS for Becton, Dickinson and Company stands at $4.19. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$194.00

average of 10 firms, last 12 months

 

$194.00

Low $159.00

Median $190.00

High $242.00

 

Analyst Ratings

Hold13 firms, last 12 months
  • Strong Buy0
  • Buy7
  • Hold5
  • Sell1
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Sep 2027Next YearFY Sep 2028
Avg. estimate$2.35$3.02$13.25$14.23
Low estimate$2.28$2.98$13.12$13.85
High estimate$2.63$3.12$13.77$14.45
No. of analysts8888
Year-ago EPS$2.29$2.90$4.091—
Growth+2.6%+4.3%——

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Sep 2027Next YearFY Sep 2028
Avg. estimate$4.50B$4.79B$19.75B$20.58B
Low estimate$4.32B$4.76B$19.71B$20.39B
High estimate$5.19B$4.82B$19.83B$21.14B
No. of analysts771010
Year-ago revenue$5.25B$4.71B$19.46B—
Growth-14.4%+1.6%+1.5%—
Recent analyst actions15 rating and price-target changes, latest Nov 10, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Becton, Dickinson and Company. Becton, Dickinson and Company has reported as a listed company since 1973. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold BDX20 companies · 8 funds
Compare BDX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ABTAbbott LaboratoriesMedical - Devices$186.1B
  • BAXBaxter International Inc.Medical - Instruments & Supplies$13.2B
  • BLFSBioLife Solutions, Inc.Medical - Instruments & Supplies$1.9B
  • EMBCEmbecta Corp.Medical - Instruments & Supplies$354M
  • ICUIICU Medical, Inc.Medical - Instruments & Supplies$4.5B
  • MDTMedtronic plcMedical - Devices$131.6B
  • MMSIMerit Medical Systems, Inc.Medical - Instruments & Supplies$5.2B
  • SOLVSolventum CorporationMedical - Instruments & Supplies$15.1B

More Medical - Instruments & Supplies companies

  • STAASTAAR Surgical CompanyNASDAQ$1.3B
  • STSSSharps Technology, Inc.NASDAQ$54M
  • STVNStevanato Group S.p.A.NYSE$4.2B
  • STXSStereotaxis, Inc.AMEX$80M
  • SUVPFSartorius AGOTC$18.7B
  • SVSOSheerVision, Inc.OTC$2,551
  • TCGGYTecan Group AGOTC$2.3B
  • TCHBFTecan Group AGOTC$2.2B
  • TDVXFTobii Dynavox AB (publ)OTC$982M
  • TFXTeleflex IncorporatedNYSE$6.2B
  • TGLVYTop Glove Corporation Bhd.OTC$1.1B
  • TRJ.AXTrajan Group Holdings LimitedASX

ETFs holding Becton, Dickinson and Company

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.08%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.07%
  • VOVanguard Mid-Cap ETF$103.4B in assets0.52%
  • IVViShares Core SP 500 ETF$852.9B in assets0.09%
  • IHIiShares US Medical Devices ETF$4.0B in assets4.89%
  • EQTYKovitz Core Equity ETF$1.4B in assets4.39%
  • BASVBrown Advisory Sustainable Value ETF$434M in assets3.74%
  • FPAGFPA Global Equity ETF$673M in assets3.57%

Largest holders first, then the funds most concentrated in BDX.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Becton, Dickinson and Company, and how their positions are changing. At a $58.96B market value, institutional positions materially move Becton, Dickinson and Company's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Becton, Dickinson and Company executives and directors. Shares of Becton, Dickinson and Company have traded between $162.29 and $251.99 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Becton, Dickinson and Company. Becton, Dickinson and Company is a $58.96B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Becton, Dickinson and Company. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Becton, Dickinson and Company. Coverage tracks Becton, Dickinson and Company within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Becton, Dickinson and Company.

BDX Analysis
Fair
Past4
Growth3
Health3
Profit1
Value1

News

Latest Market News